This paper sets out to explore the relationship between pharmaceutical innovation, its industrial dependence on patent protection, the advent of cheaper generics after patent expiry and the cumulative impact of these issues and events on healthcare payers. Three observations will help to set the scene.
These relationships are not static, but dynamic. They change over time as the pendulum tends to swing.
The issues under observation are heavily politicised because the conduct, financing and outcome of healthcare are all politically controversial and influential in general elections.
Pharmaceuticals are both an industry and a component of healthcare. The political balance, at government level, between healthcare policy and industrial policy for pharmaceuticals will profoundly affect the prospects of both the research-based and the generics sector of the industry. Historically, the two sectors became clearly distinguishable in the 1930s.
ChainE.FloreyH.W.GardnerA.D. (1940) ‘Penicillin as a chemotherapeutic agent’LancetVol. 239, p. 226.
2.
RedwoodH. (1988) ‘The Pharmaceutical Industry — Trends, Problems and Achievements’, Oldwicks Press, Felixstowe, Suffolk, p. 46.
3.
RedwoodH. (1990) ‘Patent Term Restoration for the 1990s’, Oldwicks Press, Felixstowe, Suffolk, pp. 60–64.
4.
Official Journal of the European Communities (1992) ‘Council Regulation (EEC) No.1758/92 of 18 June 1992 concerning the creation of a supplementary protection certificate for medicinal products’, No. L 182/1, 2nd July.
5.
World Trade Organization (1994) ‘Agreement on trade-related aspects of intellectual property rights, including trade in counterfeit goods’, Annex 1C of Agreement Establishing the World Trade Organization, signed in Marrakesh, 15th April.
6.
RedwoodH. (2002) ‘Where is the pharma industry going — Insights for the new millennium?’, Scrip Reports (BS 1164), PJB Publications Ltd, Richmond, Surrey.
7.
European Editorial (2002) ‘Boosting generic substitution’Pharma Pricing & ReimbursementVol. 7, No. 11, p. 319.
8.
SchulzA. (2003) ‘Outlook bright for generics’World Generic MarketsVol. 5, No. 12, pp. 16–17; see also AlbaneseV. (2003) ‘Le développement des génériques — suspendus aux décisions gouvernementales’, Pharmaceutiques, Vol. 105, pp. 31–37.
9.
AlbaneseV. (2002) ‘Prix de référence générique — Inquiétudes industrielles et officinales’PharmaceutiquesVol. 100, October, pp. 8–9.
10.
European Federation of Pharmaceutical Industries and Associations (EFPIA) (2003) ‘Future medicines legislation’, October (available online at http://www.efpia.org).
11.
European Generic medicines Association (EGA) (2003) ‘EU member states must tackle the EC Commission's failure to promote pharmaceutical competition and affordability’, Press Release, 22nd April.
12.
World Trade Organization (2001) ‘Declaration on the TRIPS agreement and public health’, adopted on 14th November by the Fourth Session of the WTO Ministerial Conference held in Doha, Qatar.
13.
Anon. (2001) ‘US secures price cuts for Cipro’ and ‘Canada to buy Cipro from Bayer’, Scrip, 26th October, pp. 18–19.
LueckS. (2003) ‘Senate clears bill expanding Medicare coverage’, Wall Street Journal, 26th November, p. A3.
19.
RobinsonR. (2000) ‘Managed care in the United States: A dilemma for evidence-based policy?’Health EconomicsVol. 9, pp. 1–7.
20.
AnsellJ. (2001) ‘Taking the real measure of pharma's prospects’, Scrip Magazine, Parts I–III, May, June, July–August issues.
21.
Fleming's1928 discovery of penicillin was not applicable in practical medicine until after Chain et al. succeeded in purifying it in 1940 (see ref. 1).
22.
MoskowitzD.B. (2001) ‘Health plans end in tiers’, Scrip Magazine, November, pp. 38–40.
23.
BeardK.ForresterE.LeeA. (1998) ‘Systems and strategies for managing the drugs budget in Glasgow’British Medical JournalVol. 317, pp. 1378–1381.
24.
ZugerA. (2003) ‘Rx: Canadian drugs’New England Journal of MedicineVol. 349, No. 23, pp. 2188–2190.
25.
MacarthurD. (2000) ‘Reimbursement of new drugs in Japan: A complex system edging towards reform’, Spectrum Life Sciences, October, Decision Resources, Waltham, Massachusetts.
26.
Financial Times (2003) ‘Business of chemicals — Hopes rise that the worst is over’, Special Report, 10th September.
27.
Financial Times (2003) ‘Koch buys DuPont textile unit’ 18th November, p. 32.
28.
PenyJ.-P. (2003) ‘How bright is the future for generics?’, Scrip Magazine, March, pp. 13–17.
29.
RedwoodH. (2003) ‘Towards a mid-Atlantic model of health care — A European perspective’, in KlusenN.MeuschA. (eds) ‘Europäischer Binnenmarkt und Wettbewerb: Zukunftsszenarien für die GKV, Nomos-Verlag, Baden-Baden (in English).
30.
European Commission, Enterprise Directorate-General (2000) ‘Aims and tasks of the unit responsible for pharmaceuticals’, Luxembourg.
31.
RedwoodH. (2002) ‘Whatever happened to industrial policy?’, Scrip Magazine, October, pp. 7–9.
